Abstracts

Embrace, a wearable convulsive seizure detection and alert system - First performance report of a case study in real-life settings

Abstract number : 3.079
Submission category : 1. Translational Research: 1D. Devices, Technologies, Stem Cells
Year : 2016
Submission ID : 198671
Source : www.aesnet.org
Presentation date : 12/5/2016 12:00:00 AM
Published date : Nov 21, 2016, 18:00 PM

Authors :
Rosalind Picard, Media Lab (Massachusetts Institute of Technology) and Empatica Inc; Giulia Regalia, Empatica Inc; Chiara Caborni, Empatica Inc; Matteo Migliorini, Empatica Inc; and Francesco Onorati, Empatica Inc

Rationale: Empatica (www.empatica.com) is working on the development of an automated comfortably wearable convulsive seizure (CS) detection system relying on accelerometer (ACC) and electrodermal activity (EDA) data (Epilepsia 2012, 53, 93-7). Using machine learning algorithms trained on generalized tonic-clonic seizures (GTCS) gathered inside Epilepsy Monitoring Units (EMUs), the system has achieved sensitivity (Se) of 92-100% and false alarm (FA) rates ranging from 0.48 to 2.02 false alarms per day (Regalia et al. 2015, American Epilepsy Society Annual Meeting; Onorati et al. 2016, Epilepsy Pipeline Conference, Caborni et al. 2016, Partners Against Mortality in Epilepsy). However, EMU settings do not mimic the real-life environment where the system is intended for use. In real-life settings people are engaged in very different physical activities, such as sports and physical labor, which may result in higher FA rates. Moreover, the dynamic and semiology of CSs occurring outside EMUs might be different, influencing their detection. In this work we present a case study from a real-life setting. Methods: Embrace is a wrist-worn device and smartphone-based alert system which analyses 3-axis acceleration and EDA data from the patient and provides an alert to designated caregivers when an unusual event is detected. The Embrace and alert system are being evaluated in an IRB-approved clinical trial. This case study is of a patient with Dravet Syndrome (14 y.) enrolled in the trial of Embrace in the outpatient setting. No data from this patient was used in training the system. In order to evaluate performance, the patient's caregiver was asked to meticulously annotate the occurrence of each CS and any activity that generated an alert. The number of FA's was obtained by subtracting the number of correctly recognized CSs from the total alerts fired by the device. The Se was the percentage of CSs that automatically triggered an alert. Results: Over a period of 113 days, the patient wore the device for 82 days (i.e., 1973 hours, average hours per day: 17.2). The system detected 22 out of 24 CSs (Se=92%). The 2 missed seizures were characterized by a mild motor component and brief duration ( < 50 sec). Figure 1 depicts the distribution of the patient's seizures according to the hour of the day. The total number of FA was 39, for a FA rate of 0.48 per day worn. FAs were generated by activities such as hands clapping/shaking, car transport and dancing. Conclusions: In this work, we have reported the performance of an unobtrusive CS detector used by a patient for a period of more than 3 months in a real-life setting, where none of the patient's data had been used in training the system. The performance, both Se and FA rates, were in the same range as those for data gathered in best-case clinical settings. In ongoing research with more patients, we are seeing similar results. At AES, and in future publications, we will present more detailed evaluations with other patients and healthy subjects engaged in diverse real-life activities. Funding: -
Translational Research